$3.52 Million in Sales Expected for ADMA Biologics Inc (NASDAQ:ADMA) This Quarter

Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to announce sales of $3.52 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for ADMA Biologics’ earnings. The highest sales estimate is $3.94 million and the lowest is $3.10 million. ADMA Biologics reported sales of $2.27 million during the same quarter last year, which indicates a positive year over year growth rate of 55.1%. The business is expected to issue its next quarterly earnings results on Friday, August 11th.

On average, analysts expect that ADMA Biologics will report full year sales of $3.52 million for the current year, with estimates ranging from $19.75 million to $20.10 million. For the next year, analysts anticipate that the firm will report sales of $38.71 million per share, with estimates ranging from $28.32 million to $49.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.23. The company had revenue of $2.63 million for the quarter, compared to analyst estimates of $3.35 million.

ADMA has been the subject of several analyst reports. Maxim Group reissued a “buy” rating and issued a $13.00 target price on shares of ADMA Biologics in a research note on Wednesday, June 28th. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

ADMA Biologics (NASDAQ ADMA) traded up 2.37% during mid-day trading on Wednesday, hitting $3.45. 15,905 shares of the company traded hands. The stock’s market capitalization is $44.46 million. ADMA Biologics has a one year low of $2.93 and a one year high of $8.00. The company’s 50-day moving average is $3.46 and its 200-day moving average is $4.30.

ILLEGAL ACTIVITY WARNING: “$3.52 Million in Sales Expected for ADMA Biologics Inc (NASDAQ:ADMA) This Quarter” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/3-52-million-in-sales-expected-for-adma-biologics-inc-nasdaqadma-this-quarter-updated-updated.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about ADMA Biologics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ADMA Biologics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit